The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning sign. Researchers analyzing millions of medical records found that people ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...